3D BioAnalytiX Awarded $840,000 NIH Grant to Advance Earlier Detection of ATTR Heart Failure

SAN DIEGO - Rezul -- 3D BioAnalytiX Inc., a San Diego-based biotechnology company developing structural proteomics technologies for earlier disease detection and a 2026 Connect Cool Company, has been awarded approximately $840,000 through the National Heart, Lung, and Blood Institute CATALYZE Program to advance clinical validation of the AmyFold Assay.

The two-year R33 award will support multicenter and longitudinal validation of the AmyFold Assay, a blood-based test designed to detect disease-associated transthyretin, or TTR, misfolding. The project will be led by Sandra Pankow, Ph.D., founder and CEO of 3D BioAnalytiX and principal investigator of the award, in collaboration with investigators at The Scripps Research Institute, Cleveland Clinic, Cedars-Sinai Smidt Heart Institute and Chaparral Inc.

More on Rezul News

• Sawgrass Ford President Attributes Dealerships Success to Long-Term Employees
• Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day
• Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
• Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
• Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence

Transthyretin amyloidosis, or ATTR, is a progressive and substantially underdiagnosed disease and an increasingly recognized cause of heart failure, particularly among older adults. Diagnosis often occurs only after significant cardiac damage has developed, despite the availability of therapies that can slow disease progression.

The AmyFold Assay is designed to identify TTR misfolding, one of the earliest causative molecular events associated with ATTR. Clinical data generated by 3D BioAnalytiX to date suggest the molecular change may be detectable years before ATTR is typically diagnosed using current clinical approaches, with longitudinal data indicating a potential 10- to 20-year earlier detection window.

"Earlier detection could fundamentally change how ATTR is managed because patients have the greatest opportunity to benefit when treatment begins before irreversible organ damage occurs," Pankow said. "This award gives us the opportunity to rigorously validate the AmyFold Assay across multiple clinical settings and move the technology closer to clinical implementation."

More on Rezul News

• Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
• Headline: House of Nova Paints Every Face in Gold at New York Fashion Week
• Can Government Operate Better Through Innovation?
• MAD Properties Group's Give Back Program Returns Commission Dollars to Military Buyers and Sellers
• Pinnacle Home Improvements Named Best Siding Company in Atlanta by My Home Improvement Magazine

The NHLBI CATALYZE award provides significant non-dilutive support for the next stage of the AmyFold Assay's development while advancing a diagnostic technology developed within San Diego's research and biotechnology ecosystem.

With near-term clinical validation supported by the award, 3D BioAnalytiX is also preparing to raise a seed round to accelerate clinical implementation, regulatory development and commercialization of the AmyFold Assay.

For Connect, the award reflects the continued momentum of its 2026 Cool Companies cohort and the potential for San Diego-based science to translate into technologies that change when disease can be detected and treated.

Connect with Sandra Pankow on LinkedIn:
https://www.linkedin.com/in/sandra-pankow-81277133/

Learn more about 3D BioAnalytiX:
www.3dbioanalytix.com